Education
About Us
Working with TipRanks
Follow Us
Arvinas Holding Company (ARVN)
NASDAQ:ARVN
ARVN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.94 - $37.38
Previous CloseN/A
Volume216.17K
Average Volume (3M)3.20M
Market Cap
$563.49M
Enterprise Value-$433.25M
Total Cash (Recent Filing)$81.00M
Total Debt (Recent Filing)$10.50M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Jul 31, 2025EPS Estimate
-0.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.14
Shares Outstanding72,991,390
10 Day Avg. Volume4,018,495
30 Day Avg. Volume3,197,467
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda4.76
Forecast
1Y Price Target
$20.68Price Target Upside210.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
---
Bulls Say, Bears Say
Bulls Say
Cost ManagementReduction in Arvinas workforce improves cash runway, mitigating funding concerns.
Pipeline PotentialArvinas’ early pipeline, including LRRK2, BCL6, and G12D degraders, is worthy of attention and could see initial proof of concept in Neuro & Heme.
Strategic FocusArvinas and Pfizer will double-down on efforts to launch vepdeg in the narrower 2L+ ESR1m population, where VERITAC-2 yielded positive data.
Bears Say
Clinical TrialsVepdegestrant will not move forward with two previously planned Phase 3 trials, narrowing its opportunity.
Market CompetitionPfizer opts not to invest further capital in vepdeg line-extensions due to competitive data coming from Roche’s giredestrant and Astra’s camizestrant.
Partnership ImpactDiscontinuation of combination programs with Pfizer lowers confidence in the true potential of vepdegestrant.
---
Ownership Overview
2.70% Insiders
24.07% Mutual Funds
0.33% Other Institutional Investors
57.23% Public Companies and
Individual Investors
ARVN FAQ
What was Arvinas Holding Company’s price range in the past 12 months?
Arvinas Holding Company lowest stock price was $5.93 and its highest was $37.38 in the past 12 months.
What is Arvinas Holding Company’s market cap?
Arvinas Holding Company’s market cap is $563.49M.
When is Arvinas Holding Company’s upcoming earnings report date?
Arvinas Holding Company’s upcoming earnings report date is Jul 31, 2025 which is in 83 days.
How were Arvinas Holding Company’s earnings last quarter?
Arvinas Holding Company released its earnings results on May 01, 2025. The company reported $1.14 earnings per share for the quarter, beating the consensus estimate of -$0.965 by $2.105.
Is Arvinas Holding Company overvalued?
According to Wall Street analysts Arvinas Holding Company’s price is currently Undervalued.
Does Arvinas Holding Company pay dividends?
Arvinas Holding Company does not currently pay dividends.
What is Arvinas Holding Company’s EPS estimate?
Arvinas Holding Company’s EPS estimate is -0.94.
How many shares outstanding does Arvinas Holding Company have?
Arvinas Holding Company has 72,991,390 shares outstanding.
What happened to Arvinas Holding Company’s price movement after its last earnings report?
Arvinas Holding Company reported an EPS of $1.14 in its last earnings report, beating expectations of -$0.965. Following the earnings report the stock price went down -24.844%.
Which hedge fund is a major shareholder of Arvinas Holding Company?
Currently, no hedge funds are holding shares in ARVN
---
Arvinas Holding Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.68 (210.04% Upside)
$20.68 (210.04% Upside)
Blogger Sentiment
Bullish
ARVN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 54.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $329.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-78.45%
12-Months-Change
Fundamentals
Return on Equity
-35.41%
Trailing 12-Months
Asset Growth
-17.44%
Trailing 12-Months
Company Description
Arvinas Holding Company
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
---
ARVN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive sentiment with significant progress in clinical trials, especially for Vepdegestrant and ARV-102. However, the removal of planned phase 3 trials and workforce reductions indicate challenges and strategic realignments.Read More>---
ARVN Stock 12 Month Forecast
Average Price Target
$20.68
▲(210.04% Upside)
Technical Analysis
Niagen Bioscience
―
Immatics
―
Opthea Limited Sponsored ADR
―
PureTech Health
―
Sionna Therapeutics, Inc.
―
---